Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Gains from Sales and Divestitures (2018 - 2026)

Aytu Biopharma has reported Gains from Sales and Divestitures over the past 8 years, most recently at $81119.0 for Q4 2025.

  • Quarterly Gains from Sales and Divestitures rose 932.97% to $81119.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $81119.0 through Dec 2025, up 932.97% year-over-year, with the annual reading at $1608.0 for FY2025, 93.81% down from the prior year.
  • Gains from Sales and Divestitures was $81119.0 for Q4 2025 at Aytu Biopharma, up from $1618.0 in the prior quarter.
  • Over five years, Gains from Sales and Divestitures peaked at $642696.0 in Q2 2022 and troughed at $333.0 in Q4 2022.
  • The 5-year median for Gains from Sales and Divestitures is $7853.0 (2024), against an average of $55605.7.
  • Year-over-year, Gains from Sales and Divestitures crashed 96.26% in 2021 and then surged 6351.48% in 2022.
  • A 5-year view of Gains from Sales and Divestitures shows it stood at $1972.0 in 2021, then tumbled by 83.11% to $333.0 in 2022, then surged by 238.14% to $1126.0 in 2023, then skyrocketed by 597.42% to $7853.0 in 2024, then soared by 932.97% to $81119.0 in 2025.
  • Per Business Quant, the three most recent readings for AYTU's Gains from Sales and Divestitures are $81119.0 (Q4 2025), $1618.0 (Q3 2025), and $1608.0 (Q2 2025).